Hyzaar 50-12.5

This page contains recent news articles, when available, and an overview of Hyzaar 50-12.5 but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

HYZAAR(R) 100-12.5 mg Offers A New Convenient Dosing Option Within …  -  Oct 21, 2005
WHITEHOUSE STATION, NJ -- Merck & Co., Inc., today announced the availability of HYZAAR(R) 100-12.5 mg (losartan potassium/hydrochlorothiazide tablets), ... $4.95 - Business Wire - ECNext

FDA Approves HYZAAR as the First and Only Fixed-Dose Combination …  -  Apr 14, 2005
WHITEHOUSE STATION, NJ -- Merck & Co., Inc. today announced that the US Food and Drug Administration (FDA) has approved another new indication for HYZAAR(R) ... $4.95 - Business Wire - ECNext

For Patients with Hypertension and Left Ventricular Hypertrophy, FDA ...  -  Apr 18, 2005
Merck & Co, Inc announced that the US Food and Drug Administration (FDA) has approved another new indication for HYZAAR(reg), Merck's fixed-dose combination ... Medical News Today - Medical News Today (press release)

FDA Approves HYZAAR As the First and Only Fixed-Dose Combination …  -  Apr 14, 2005
Merck & Co., Inc. today announced that the US Food and Drug Administration (FDA) has approved another new indication for HYZAAR(R), Merck's fixed-dose ... RedOrbit

FDA Approves HYZAAR(R) as First/Only Fixed-Dose Combination …  -  May 16, 2005
Merck & Co, Inc announced that the US Food and Drug Administration (FDA) has approved another new indication for HYZAAR(R), Merck's fixed-dose combination ... Medical News Today - Medical News Today (press release)

Boniva, Hyzaar.(New & Approved)  -  Jun 1, 2005
A once-monthly oral formulation of a bisphosphonate for treating postmenopausal osteoporosis. The third bisphosphonate and the first monthly formulation ... Pay-Per-View - Family Practice News - Factiva, from Dow Jones

Ways to treat hypertension without drugs.(Focus)(Brief article) |...  -  Sep 29, 2008
Ways to treat hypertension without drugs.(Focus)(Brief article) ... find Chain Drug Review articles. This month's featured continuing education program ... Pay-Per-View - Chain Drug Review - HighBeam Research

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.